Autolus Therapeutics plcMost RecentMiscellaneousT-Cell Pipeline Is a Key Growth Driver for Autolus TherapeuticsThe 12-month consensus analyst recommendation for Autolus Therapeutics (AUTL) on September 25 is a “strong buy.”
MiscellaneousT-Cell Pipeline Is a Key Growth Driver for Autolus TherapeuticsThe 12-month consensus analyst recommendation for Autolus Therapeutics (AUTL) on September 25 is a “strong buy.”
